Global Patient Derived Xenograft/PDX Models Market

The global Patient Derived Xenograft/PDX Models Market was valued at USD 66.9 million in 2016 and is projected to reach USD 256.40million by 2025, growing at a CAGR of 16.1% from 2017 to 2025.
Patient derived tumor xenografts (PDTX) are created when cancerous tissue from a patient's primary tumor is implanted directly into an immunodeficient mouse. PDTX models are providing solutions to the challenges that researchers face in cancer drug research such as positive tumor responses in mouse models but not translating over when the study is implemented in humans. As a result, PDTX cancer models are becoming popular models to use in cancer drug research.
Sample Infographics:


Market Dynamics:
1. Market Drivers
1.1 Increasing Demand for Personalizes healthcare
1.2 GrowingInvestment in Cancer studies from private as well as govt. Sector
1.3 Growing R&D activities

2. Market Restraints
2.1 High cost of PDX models
2.2 Clinical Testing Stringent rules and ethical issues

Market Segmentation:
1. Global Patient Derived Xenograft/PDX Models Market, by Tumor type:
1.1 Gastrointestinal Tumor Models
1.2 Gynecological Tumor Models
1.3 Respiratory Tumor Models
1.4 Urological Tumor Models
1.5 Hematological Tumor Models
1.6 Other Tumor Models

2. Global Patient Derived Xenograft/PDX Models Market, by Type:
2.1 Rat Models
2.2 Mice Models

3. Global Patient Derived Xenograft/PDX Models Market, by End User:
3.1 Pharmaceutical & Biotechnology Companies
3.2 Contract Research Organizations
3.3 Academic & Research Institutions

4. Global Patient Derived Xenograft/PDX Models Market, by Application:
4.1 Preclinical Drug Development and Basic Cancer Research
4.2 Biomarker Analysis

5. Global Patient Derived Xenograft/PDX Models Market, by Region:
5.1 North America (U.S., Canada, Mexico)
5.2 Europe (Germany, UK, France, Rest of Europe)
5.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
5.4 Latin America (Brazil, Argentina, Rest of Latin America)
5.5 Middle East & Africa

Competitive Landscape:
The major players in the market are as follows:
1. Crown Bioscience Inc.
2. the Jackson Laboratory
3. Champions Oncology, Inc.
4. Charles River Laboratories International, Inc.
5. WuXiApptec (Group of Subsidiaries Under WuXiPharmatec)
6. ONCODESIGN
7. Horizon Discovery Group PLC (Sage Labs, Inc.)
8. Pharmatest Services Ltd.
9. Hera Biolabs
10. EPO Berlin-Buch GmbH
11. Xentech
12. Urolead
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Patient Derived Xenograft/PDX Models Marketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.

To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.